Recce Pharmaceuticals Ltd. announced the China National Intellectual Property Administration has formally granted Recce a new family two patent, Copolymer and Method for Treatment of Bacterial Infection, for its anti-infectives, with expiry in 2035. This is the final of Recce?s wholly-owned patents granted for family two, with the Company now patent-protected in all major pharmaceutical markets globally. The Chinese patent claims relate to RECCE 327 (R327) and RECCE 529 (R529), including their methods of manufacture, administration, and application to treat a broad range of common human infections.
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
0.57 AUD | -2.56% | 0.00% | +6.54% |
EPS Revisions
Annual profits - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
+6.54% | 79.23M | |
+40.73% | 739B | |
+32.83% | 598B | |
-6.30% | 353B | |
+15.15% | 318B | |
+4.05% | 285B | |
+15.00% | 240B | |
+9.78% | 210B | |
-5.52% | 206B | |
+6.17% | 164B |
- Stock Market
- Equities
- RCE Stock
- News Recce Pharmaceuticals Ltd
- Recce Pharmaceuticals Ltd Receives New Patent in China for RECCE Anti-Infectives from China National Intellectual Property Administration